Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kentaro Tajima"'
Autor:
Kentaro Tajima, Tomofumi Ishikawa, Masami Tsuchiya, Masafumi Kikuchi, Taku Obara, Nariyasu Mano
Publikováno v:
Pharmacoepidemiology, Vol 2, Iss 1, Pp 13-25 (2023)
We aimed to evaluate the adverse birth outcomes of anticancer drug prescription during pregnancy using a Japanese claims database from 2005 to 2019. We applied validated claims-based algorithms to identify pregnant women with birth outcomes, and eval
Externí odkaz:
https://doaj.org/article/b08fdb97dc1544cfb2c746eae95f80cf
Publikováno v:
Future Oncology.
Aim: To evaluate treatment patterns of novel therapies (inotuzumab ozogamicin (inotuzumab), blinatumomab, and tisagenlecleucel) in patients with acute lymphoblastic leukemia (ALL) in a Japanese real-world setting. Patients & Methods: Patients with AL
Autor:
Kentaro Tajima, Tomofumi Ishikawa, Aoi Noda, Fumiko Matsuzaki, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano
Publikováno v:
Current Medical Research and Opinion. 38:1651-1654
When using administrative data, validation is essential since these data are not collected for research purposes and misclassification can occur. Thus, this study aimed to develop algorithms identifying pregnancy and to evaluate the validity of admin
Autor:
Kentaro Tajima, Tomofumi Ishikawa, Fumiko Matsuzaki, Aoi Noda, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano
Publikováno v:
International Journal of Environmental Research and Public Health; Volume 19; Issue 8; Pages: 4864
This study aimed to develop and validate claims-based algorithms for identifying live birth, fetal death, and cesarean section by utilizing administrative data from a university hospital in Japan. We included women who visited the Department of Obste
Autor:
Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yanez, Keun Seok Lee, Igor Bondarenko, Alicia Vana, Fiona Hilton, Tomofumi Ishikawa, Kentaro Tajima, Oleg Lipatov
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(1)
PF-05280014 was compared with trastuzumab sourced from the European Union (trastuzumab-EU), each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study. Equivalence
Autor:
Kentaro Tajima, Gene S. Hall, Kazuyuki Takai, Takuya Hayashi, Keerthi Savaram, Huixin He, Mengjun Li, Eric Garfunkel, Vladimir Yu. Osipov
Publikováno v:
Carbon. 139:861-871
Current approaches for scalable production of holey graphene materials require graphene oxide or reduced graphene oxide as starting materials. The molecular basis fundamentally determines that the holey graphene materials thus generated still contain
Publikováno v:
Future oncology (London, England). 17(15)
Aim: To describe real-world breast cancer medications among reproductive-age women. Patients & methods: Using data from a Japanese claims database, anticancer prescriptions were classified into seven categories of amenorrhea risk based on fertility p
Publikováno v:
Polyhedron. 136:155-158
We evaluated graphene oxides (GOs) synthesized by different methods in terms of magnetism and chemical structure. GO samples were synthesized by Brodie and Hummers methods, which are labeled as BGO and HGO, respectively. The temperature dependence of
Publikováno v:
Future oncology (London, England). 15(12)
Biologics have dramatically changed breast cancer treatment, and trastuzumab has been an essential treatment drug for HER2-positive breast cancer. The introduction of trastuzumab biosimilar offers the potential to deliver long-term cost savings plus
Publikováno v:
Annals of Oncology. 30:vi120
Background This randomized, double-blind, multicenter study (NCT02364999) compared PF-06439535 (a potential bevacizumab biosimilar) with reference bevacizumab sourced from the EU (bevacizumab-EU; Avastin®), both with paclitaxel and carboplatin (P/C)